CD34 and acute myeloid leukemia: CD123, the alfa-subunit of the interleukin-3 (IL-3) receptor, is an attractive target, which has been reported to be expressed by the majority of AML patients, both on bulk leukemic cells and CD34+CD38− putative LSCs [14,15].